Explanation. ( ) The principal investigator is the entity charged with ensuring protocol compliance, not the IRB/IEC. (ICH 4.5.1)
|
|
- Francis Morgan
- 5 years ago
- Views:
Transcription
1 Question 1 Explanation ( ) The principal investigator is the entity charged with ensuring protocol compliance, not the IRB/IEC. (ICH 4.5.1) ( ) According to ICH GCP an IRB/IEC should safeguard the rights, safety, and well being of all trial subjects. The IRB/IEC review is to assure, both in advance and by periodic review, that appropriate steps are taken to protect the rights and welfare of humans participating as subjects in a research study. (ICH 3.1.1) ( ) An IRB is charged with protecting the rights, safety and wellbeing of trial subjects. There is no responsibility for ensuring participation. (ICH 3.1.1) ( ) An IRB/IEC reviews Informed Consent Forms in order to ensure adequate information is provided to subjects. This is a tool for ensuring patient rights safety and well-being. Question 2 ( ) According to CFR 50.25, the first basic element is: A statement that the study involves research, an explanation of the purposes of the research and the expected duration of the subject's participation, a description of the procedures to be followed, and identification of any procedures which are experimental. ( ) The basic elements require a description of any reasonably foreseeable risks or discomforts to the subject. Additional elements enumerate that a treatment or procedure may involve risks to the subject (or to the embryo or fetus, if the subject is or may become pregnant) which are currently unforeseeable. ( ) The 4 th basic element is a disclosure of appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the subject. ( ) The 7 th basic element required in an informed consent is an explanation of whom to contact for answers to pertinent questions about the research and research subjects' rights, and whom to contact in the event of a researchrelated injury to the subject. Question 3 ( ) The Kefauver-Harris Amendment is a U.S. document enacted to strengthen the FDA in regard to clinical trials and human subject protection. ( ) The Nuremburg Code is the summary ofpermissible human experiments that was never incorporated into law or regulation.
2 ( ) GCP is based on the thirteen points of the Declaration of Helsinki. ( ) The International Conference on Harmonisation formulated the GCP guidelines that are based on the Declaration of Helsinki. Question 4 ( ) False ICH GCP is a guideline, not a law. It works within the boundaries of local law. Local law supercedes the guidelines. Question 5 ( ) A qualified physician must oversee the medical decisions of the subjects. (ICH 4.3.1) ( ) Individuals involved in the conduct of the trial must be qualified through training or education for the tasks involved. (ICH 2.8) ( ) The sponsor can train some trial related tasks. Others must be designated based on local and educational requirements. (ICH 2.8) ( ) Principal #8 of GCP states, Each individual involved in conducting a trial should be qualified by education, training and experience to conduct or perform the respective task. (ICH 2.8) Question 6 ( ) Individual members with special expertise may be invited to participate in discussions, but they will not be voting members. (ICH 3.2.6) ( ) Only members who are independent of the investigator and the sponsor should vote/provide opinion on trial related matters (ICH3.2.1) ( ) Recommended that one member is expert in a non-scientific area (ICH b) ( ) At least 5 members (ICH a) Question 7 ( ) The investigator may implement a deviation from, or a change in, the protocol to eliminate an immediate hazard to trial subjects without prior IRB/IEC approval. ( ICH 4.5.4) ( ) The investigator should not implement any deviation from, or changes of the protocol except where necessary to eliminate an immediate hazard to trial subjects. (ICH 4.5.2) ( ) The investigator/institution should conduct the trial in compliance with the
3 protocol agreed to by the sponsor The investigator/institution and the sponsor should sign the protocol, or an alternative contract, to confirm the agreement. (ICH 4.5.1) Many IRB/IECs have an institutional representative to confirm institutional ability to comply prior to approval. ( ) Correct answer is A Question 8 ( ) False. IRB procedures should specify that no subject should be admitted to a trial before the IRB/IEC issues its written approval of the trial (ICH 3.3.6). Question 9 ( ) A duly constituted IRB has reviewed and approved the investigational product protocol without an informed consent. (CFR Section d) ( ) The subject is in a life-threatening situation and the risks are reasonable in relation to the medical condition. (CFR Section iii). ( ) If immediate use of the test article is required to preserve the life and time is not sufficient to obtain legal representative permission, and all other criteria of approval have been satisfied, the waiver may be implemented. (CFR 50.23, sections 2 and 3). ( ) If immediate use of the test article is (opinion) required to preserve the life of the subject and time is not sufficient to obtain consent, and all others have been satisfied, the article may be used and documentation will be provided at a later time. (CFR section b). Question 10 ( ) False. Research participants are randomized in clinical trials so that bias does not weaken the study results. The chance of a subject receiving Investigational Product is based on protocol design, not randomization. Question 11 ( ) Treating the adverse event means stopping the investigational therapy (if applicable) and treating any symptoms or sequellae. Breaking the blind is not necessary unless it might change the therapy. ( ) Most informed consents specifically state that even if a patient withdraws from the trial, the blind will not be broken. Only when the safety profile can be altered by breaking the blind, should the patient designation be revealed. ( ) Unblinding is not done until all statistical tests have been completed. Persons responsible for analysis and interpretation of results should maintain the blind
4 until all testing is complete. (ICH E2A Section D) ( ) When a patient s treatment might change based on knowing the treatment assignment, the need to know overcomes the need to minimize bias. Question 12 ( ) The investigator should conduct the trial in compliance with the protocol agreed to by the sponsor, which was given approval by the IRB. (ICH 4.5.1). ( ) The investigator should have available an adequate number of qualified staff and adequate facilities to conduct the trial safely and properly. (ICH 4.2.3) ( ) The sponsor should expedite the reporting to all concerned and to the regulatory authorities of all ADRs. (ICH 5.17). ( ) During and following subject participation, the investigator should ensure that adequate medical care is provided to a subject for any adverse events. (ICH 4.3.2) Question 13 ( ) Sponsor is responsible for written SOPs to ensure that trials are conducted and data are generated in accordance with the protocol (ICH 5.1.1) ( ) Prior to entering an agreement with the investigator, the sponsor should provide the investigator with the protocol and an up-to-date Investigator Brochure (ICH 5.6.2) ( ) Providing adequate medical care is an investigator responsibility (ICH 4.3.1) ( ) The sponsor is responsible for ongoing safety evaluation of the investigational product(s). (ICH 5.16) Question 14 ( ) Summary of findings from non-clinical studies that potentially have clinical significance and from clinical trials that are relevant to the trial. (ICH 6.2.2) Only including positive trials does not follow the guidelines. ( ) Description of the population to be studied. (ICH 6.2.6) ( ) A detailed description of the objectives and the purpose of the trial. (ICH 6.3) A detailed description of the trial design that should include endpoints and other pertinent descriptions. (ICH 6.4) ( ) A statement that the trial will be conducted in compliance with the protocol, GCP and applicable regulatory requirements. (ICH 6.2.5)
5 Question 15 ( ) False The guidance does not bind the FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statute, regulations or both. (Introduction E6 GCP Guidance)
Roles & Responsibilities of Investigator & IRB
Roles & Responsibilities of Investigator & IRB Jaranit Kaewkungwal Mahidol University Regulatory & Guidelines Regulatory & Guidelines GCP & Computer / Database Management Systems International Conference
More informationThe SOP applies to all human subject research falling under the purview of the University of Missouri Institutional Review Board.
Institutional Review Board.... University of Missouri-Columbia.. Standard Operating Procedure Informed Consent Types and Elements Informed Consent Types and Elements Effective Date: December 12, 2005 Original
More informationResearch Audits PGR. Effective: 12/04/2013 Reviewed: 12/04/2015. Name of Associated Policy: Palmetto Health Administrative Research Review
Effective: 12/04/2013 Reviewed: 12/04/2015 Name of Associated Policy: Palmetto Health Administrative Research Review Definitions Responsible Positions Equipment Needed Procedure Steps, Guidelines, Rules,
More informationDr. R. Sathianathan. Role & Responsibilities of Principal Investigators in Clinical Trials. 18 August 2015
18 August 2015 Role & Responsibilities of Principal Dr. R. Sathianathan Professor of Psychiatry, SRMC, Porur & Former Director, Institute of Mental Health, Chennai Principal Investigators & GOOD CLINICAL
More informationGood Clinical Practice. Lisa de Blieck MPA CCRC Clinical Trials Coordination Center
Good Clinical Practice Lisa de Blieck MPA CCRC Clinical Trials Coordination Center Good Clinical Practice (GCP) An international standard for the design, conduct, performance, monitoring, auditing, recording,
More informationETHICAL AND REGULATORY CONSIDERATIONS
CONSIDERATIONS Office for Office for Human Research Protections The Office for Office for Human Research Protections (OHRP) is an administrative subdivision within the U.S. Department of Health and Human
More information(Type inside gray boxes, cells will expand) A. EIGHT POINT CRITERIA for IRB Review
Page 1 of 5 IRB Reviewers 8-Point Analysis Form Based on Federal Policy for the Protection of Human Subjects, Criteria for IRB Approval of Research (45 CFR 46.111) Protocol ID #/Title: Date of Review:
More informationAPEC Preliminary Workshop: Review of Drug Development in Clinical Trials
APEC Preliminary Workshop: Review of Drug Development in Clinical Trials Session 9 B Clinical Trial Assessment Patient Protection Informed Consent Susan D Amico Vice President and Global Head Clinical
More information12.0 Investigator Responsibilities
12.0 Investigator Responsibilities 12.1 Policy Investigators are ultimately responsible for the conduct of research. Research must be conducted according to the signed Investigator statement, the investigational
More informationA Principal Investigator s Guide to Responsibilities, Qualifications, Records and Documentation of Human Research University of Kentucky
A Principal Investigator s Guide to Responsibilities, Qualifications, Records and Documentation of Human Research University of Kentucky I. Compliance with IRB and Applicable Federal Requirements A. Investigators
More informationOverview ICH GCP E6(R2) Integrated Addendum
2017 Biomedical Research Alliance of New York LLC CITI Program is a division of BRANY Overview ICH GCP E6(R2) Integrated Addendum Introduction On 15 December 2016, the International Council for Harmonistion
More informationBIMO SITE AUDIT CHECKLIST
Item AUTHORITY AND ADMINISTRATION FOR STUDIES INVOLVING HUMAN DRUGS, BIOLOGICS AND DEVICES 1. Compare the Investigator Agreement with the information provided by the assigning Center. Auditor will check
More informationGood Clinical Practice: A Ground Level View
Good Clinical Practice: A Ground Level View Jeanna Julo, BA, BA, CCRP Assistant Director, Clinical Data Management & Quality Controls, Auditing & Training Clinical Research Administration Research Institute,
More informationTITLE: Reporting Adverse Events SOP #: RCO-204 Page: 1 of 5 Effective Date: 01/31/18
SOP #: RCO-204 Page: 1 of 5 1. POLICY STATEMENT: The research team is responsible for recognizing changes in subject health that may qualify as adverse events, classifying those results as defined in the
More informationUnofficial copy not valid
Page 2 (9) CONTENTS 1. PURPOSE... 3 2. DEFINITIONS... 3 3. RESPONSIBILITY... 3 4. INVESTIGATOR SELECTION... 3 4.1 Identification of Investigator s... 3 4.2 Initial Contacts... 4 4.3 Distribution of Pre-Study
More informationInvestigator-Initiated Studies: When you re the Sponsor. Cheri Robert & Tammy Mah-Fraser
Investigator-Initiated Studies: When you re the Sponsor Cheri Robert & Tammy Mah-Fraser ACRC Clinical Research Conference Edmonton, AB October 15, 2014 Session Objectives Define roles of the investigator,
More informationETHICS COMMITTEE: ROLE, RESPONSIBILITIES AND FUNCTIONS K.R.CHANDRAMOHANAN NAIR DEPARTMENT OF ANATOMY, MEDICAL COLLEGE, THIRUVANANTHAPURAM
ETHICS COMMITTEE: ROLE, RESPONSIBILITIES AND FUNCTIONS K.R.CHANDRAMOHANAN NAIR DEPARTMENT OF ANATOMY, MEDICAL COLLEGE, THIRUVANANTHAPURAM Outline Introduction Composition Responsibilities of IEC Responsibilities
More informationSAINT AGNES MEDICAL CENTER CLINICAL RESEARCH CENTER Fresno, California. STANDARD OPERATING PROCEDURES Institutional Review Board
SAINT AGNES MEDICAL CENTER CLINICAL RESEARCH CENTER Fresno, California STANDARD OPERATING PROCEDURES Institutional Review Board Date Effective: April 26, 2001 Index No. R 1217 Date Last Revised: 0 Date
More informationIssues of. Informed Consent. Mitchell E. Parrish, JD, RAC, CIP Regulatory Attorney
Issues of Informed Consent Mitchell E. Parrish, JD, RAC, CIP Regulatory Attorney Part I Part II Regulatory Requirements Key Considerations Part III Elements of Consent Part IV Summary 2 PART I 3 Informed
More information16 STUDY OVERSIGHT Clinical Quality Management Plans
16 STUDY OVERSIGHT... 1 16.1 Clinical Quality Management Plans... 1 16.2 Site Visits by the LOC, SDMC and LC... 2 16.3 Protocol Team Oversight... 3 16.4 Oversight of Reportable Protocol Deviations... 3
More informationDocumenting the Story of a Clinical Trial: Concept to CAPA. Lori T. Gilmartin Gilmartin Consulting LLC
Documenting the Story of a Clinical Trial: Concept to CAPA Lori T. Gilmartin Gilmartin Consulting LLC The regulations represent the floor while ethical thinking is the sky. Dr. Thomas Moore Boston University
More informationDANA-FARBER / HARVARD CANCER CENTER POLICIES FOR HUMAN SUBJECT RESEARCH TITLE:
POLICY #: EDU-100 Page: 1 of 5 1. POLICY STATEMENT: Individuals who participate in research activities overseen by DF/HCC must satisfy specific training requirements in order to conduct human subject research.
More informationIRB Federal Regulations Comparison Table 4/24/01 as updated through 10/31/01
Legal Authority 45 CFR Part 46 21 USC 321-392; 21 CFR, Parts 50 and 56 Coverage All research involving human subjects conducted, All clinical investigations regulated by the FDA, including supported or
More informationOffice of the Vice Chancellor for Research Supervisory Responsibilities of Clinical Investigators
Office of the Vice Chancellor for Research Supervisory Responsibilities of Clinical Investigators Patricia Fischer, RN, CCRP Investigator Responsibilities FDA Draft Guidance May 2007 Clarifies FDA s expectations,
More informationUNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD REPORTING UNANTICIPATED PROBLEMS INCLUDING ADVERSE EVENTS
UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD REPORTING UNANTICIPATED PROBLEMS INCLUDING ADVERSE EVENTS I. PURPOSE To specify the procedures for reporting unanticipated problems,
More informationThe GCP Perspective on Study Monitoring
The GCP Perspective on Study Monitoring Heidi Judge, CCRP Sr. Clinical Trials Project Manager Clinical Trials Network and Institute Massachusetts General Hospital 1 Overview Monitoring Basics Who, What,
More informationUniversity of South Carolina. Unanticipated Problems and Adverse Events Guidelines
University of South Carolina Unanticipated Problems and Adverse Events Guidelines These guidelines define the procedures of USC for addressing unanticipated problems involving risks to research participants
More informationPablo Tebas, M.D. Joseph Quinn, RN, BSN Yan Jiang, RN, BSN, MSN
Gilead Sciences, Inc. / Protocol Number GS-US-380-1489 Page 1 of 9 PARTNER PREGNANCY FOLLOW UP CONSENT FORM Sponsor / Study Title: Protocol Number: Principal Investigator: (Study Doctor) Gilead Sciences,
More informationIRB review of international research. Pre-conference P1 FCPA 3 rd Party Due Diligence for Health Entities. Today
John Heldens, CIP, CCRP Director, UCSF Health Care Compliance Association 2011 Compliance Conference IRB review of international research Pre-conference P1 FCPA 3 rd Party Due Diligence for Health Entities
More informationBiomedical IRB MS #
Department for Human Research Protections Institutional Review Boards Biomedical IRB MS # 1035 419-383-6796 IRB.Biomed@utoledo.edu Social, Behavioral and Educational IRB MS # 944 419-530-6167 IRB.SBE@utoledo.edu
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Delegated Responsibilities in Research Projects SOP Number: 11 Version Number: 2.0 Supercedes: 1.0 Effective date: August
More informationmanaging or activities.
STANDARD OPERATING PROCEDURE Clinical Research Monitoring TITLE: Site Initiation Visit TITLE: Site Initiation Visit 1. PURPOSE SOP Number: Version: 1.0 MICHR CRM MON 002 Effective Date: 19Dec2013 1.1 This
More informationRecord or Document Type Retention Period Relevant Legal Citation(s) IRB Records: Training Records;
TEXAS HEALTH RESOUCES Table 17-III. Record Retention Schedule Human Subject Research Records and Documents Approved by THR System Performance Council (SPC): 19 January 2010 Effective Date: October 14,
More informationStudy Guide for Emergency Care Clinicians. (Version /09/2014)
Study Guide for Emergency Care Clinicians (Version 1.2 26/09/2014) Notes 1. These learning materials are aimed primarily at paramedics, ambulance nurses, emergency care practitioners and doctors recruiting
More informationDrugs and Cosmetics rules, 2013 India
Drugs and Cosmetics rules, 2013 India Dr.Pankaj Shah Professor, Dept of Community Medicine, SRMC & RI, & Member Secretary, IEC II, SRU, Chennai Three important amendments 30 th Jan 2013 1 St Feb 2013 8
More informationVersion Number: 003. On: September 2017 Review Date: September 2020 Distribution: Essential Reading for: Information for: Page 1 of 13
CONTROLLED DOCUMENT Reporting Research Incidents and Breaches Policy CATEGORY: CLASSIFICATION: PURPOSE Controlled Number: Document Policy Governance To set out the framework and principles for reporting
More informationACTIONS/PSOP/001 Version 1.0 Page 2 of 6
1. The purpose of the Pharmacy Site File To enable the designated trust pharmacy to fulfil its role and exercise appropriate control over all aspects of study medication handling, an accurately maintained
More informationRisk Assessment and Monitoring
Version 1.3 Effective date: 25 May 2012 Author: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision Chronology: Effective Date Version 1.3 25 May 2012 Version 1.2 29 January 2010
More information[Enter Organization Logo] CONSENT TO DISCLOSE HEALTH INFORMATION UNDER MINNESOTA LAW. Policy Number: [Enter] Effective Date: [Enter]
CONSENT TO DISCLOSE HEALTH INFORMATION UNDER MINNESOTA LAW I. Policy: Policy Number: [Enter] Effective Date: [Enter] A. Purpose This policy establishes consent requirements for the disclosure of health
More informationInstitutional Review Board Standard Operating Procedures. Education and Training on Human Subject Research Date Last Revised: OVERVIEW
Page 1 of 6 Document Number: IRB-P106 Version Number: 1.3 Institutional Official: David Carlisle, MD, PhD Title: Institutional Review Board Standard Operating Procedures Education and Training on Human
More informationJoint Statement on the Application of Good Clinical Practice to Training for Researchers
Joint Statement on the Application of Good Clinical Practice to Training for Researchers HRA, MHRA, Devolved Administrations for Northern Ireland, Scotland and Wales v1.1 12/10/17 Summary This joint statement
More informationThe Greenville Hospital System Office of Research Compliance and Administration HRPP Policies and Procedures
The Greenville Hospital System Office of Research Compliance and Administration HRPP Policies and Procedures Title: Western Institutional Review Board (WIRB) HRPP Policy No. 33.02 Effective Date: May 2012
More informationConducting Monitoring Visits for Investigator-Initiated Trials (IITs)
Conducting Monitoring Visits for Investigator-Initiated Trials (IITs) Clinical Research Coordinator Society (CRCS) Forum 25 July 2014 Xia Yu Clinical Research Associate Singapore Clinical Research Institute
More informationRoles of Investigators in the Managements of Clinical Trials
Roles of Investigators in the Managements of Clinical Trials Chii-Min Hwu, M.D. Section of General Medicine Department of Medicine Taipei Veterans General Hospital Learning Objectives PI Outlines How to
More informationThe Queen s Medical Center HIPAA Training Packet for Researchers
The Queen s Medical Center HIPAA Training Packet for Researchers 1 The Queen s Medical Center HIPAA Training Packet for Researchers Table of Contents Overview of HIPAA and Research 3 Penalties for violations
More informationFor questions, concerns, to provide input, or request a consultation, call HRPP staff at
Florida Department of Health Request for Determination of Whether IRB Review is Required 500-00 Determination of Whether IRB Review is Required For questions, concerns, to provide input, or request a consultation,
More informationSuccessful FDA Inspections at Investigative Sites for Clinical Trials of Drugs and Biologics
Vol. 9, No. 1, January 2013 Happy Trials to You Successful FDA Inspections at Investigative Sites for Clinical Trials of Drugs and Biologics By Swati Tendolkar The United States Food and Drug Administration
More informationGuidance for Institutional Review Boards, Clinical Investigators, and Sponsors. Exception from Informed Consent Requirements for Emergency Research
Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors Exception from Informed Consent Requirements for Emergency Research U.S. Department of Health and Human Services Food and
More informationUtilizing the NCI CIRB
Policy P15 Written By: B. Laurel Elder, Ph.D. Created: September 2, 2011 Edited Version P15.1 Utilizing the NCI CIRB PURPOSE - The purpose of this Standard Operating Procedure (SOP) is to outline the procedures
More informationFDA Medical Device Regulations vs. ISO 14155
Vol. 11, No. 9, September 2015 Happy Trials to You FDA Medical Device Regulations vs. ISO 14155 By Shawn Kennedy Medical device clinical trials must comply with 21 CFR Parts 11 (Electronic Records), 50
More informationCLINICAL RESEARCH POLICY
CLINICAL RESEARCH POLICY Approved by: Date of approval: Originator: Medical Director POLICY STATEMENT Good quality clinical research is important for furthering our understanding of the problems encountered
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Risk Assessment of NCTU Studies SOP number: TM-020 SOP category: Trial Management Version number: 02 Version date: 16
More informationPROMPTLY REPORTABLE EVENTS
PROMPTLY REPORTABLE EVENTS PURPOSE AND SCOPE To define the structure and responsibility for reporting unanticipated problems that occurs during the conduct of research. APPLICABLE REGULATIONS Policy II.02
More informationSTUDY TEAM RESPONSIBILITIES ORIENTATION FOR NEW CLINICAL RESEARCH PERSONNEL MODULE 2
ORIENTATION FOR NEW CLINICAL RESEARCH PERSONNEL MODULE 2 Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals Overall Agenda for Orientation Module 1: Introduction
More informationDANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR HUMAN SUBJECT RESEARCH
SOP #: CON-100 Page: 1 of 9 Effective Date: 2/28/17 1. POLICY STATEMENT: The research team is responsible for obtaining and documenting the informed consent of each subject who participates in research.
More informationSponsor Responsibilities. Roles and Responsibilities. EU Directives. UK Law
EU Directives Pharmacovigilance Legislation, SOPs and Reporting Louise Boldy, Governance & Safety Manager David Martin, Pharmacovigilance Monitor EU Legislation 2001/20/EC 2005/28/EC EudraLex Vol 10 UK
More informationI. HSC Review and Approval of Research Involving Children
9.0 Vulnerable Populations 9.1 Research Involving Children I. HSC Review and Approval of Research Involving Children A. The special vulnerability of children makes consideration of involving them as research
More informationMonitoring Clinical Trials
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationMargaret Huber, RN, CHRC Compliance Consultant Office of Research Compliance
Margaret Huber, RN, CHRC Compliance Consultant Office of Research Compliance 4/20/2015 Objectives Define monitoring and explain why monitoring is important in clinical trials Provide an overview of the
More informationDEPARTMENT OF HEALTH & HUMAN SERVICES WARNING LETTER. (b) (4) clinical investigation (Protocol entitled A Phase II, Multicenter,
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 WARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED Ronald Bukowski, M.D. 28099 Gates Mills
More informationVersion Number: 004 Controlled Document Sponsor: Controlled Document Lead:
Chief Investigators and Principal Investigators in Research Policy CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Policy Governance To set out the responsibilities of
More informationGeneral Administration GA STANDARD OPERATING PROCEDURE FOR Document Development and Change Control
General Administration GA 104.00 STANDARD OPERATING PROCEDURE FOR Document Development and Change Control Approval: Nancy Paris, MS, FACHE President and CEO 08 March 2012 (Signature and Date) Approval:
More informationTitle: Investigator Responsibilities. SOP Number: 1501 Effective Date: June 2, 2017
Previous Version Dates: Title: Investigator Responsibilities SOP Number: 1501 Effective Date: June 2, 2017 1 Purpose Investigators are ultimately responsible for the conduct of research. Investigators
More informationStudy Responsibilities. Choose all that apply. f. Draw/collect laboratory specimens
Wichita State University Institutional Review Board (IRB) New Study Application Investigator Information Principal Investigator must be a WSU faculty member. Students and anyone outside of WSU are listed
More informationAN OVERVIEW OF CLINICAL STUDY TASKS AND ACTIVITIES
1 AN OVERVIEW OF CLINICAL STUDY TASKS AND ACTIVITIES Key Clinical Study Tasks and Activities 2 Discussion of Key Tasks and Activities 3 Development of the Clinical Protocol and Study Materials 3 Qualification
More informationStandard Operating Procedure IRB Review of Research Subject to the Revised Common Rule
HRP Consulting is providing this sample SOP addendum to assist organizations in the event that the revised Common Rule goes into effect on January 19, 2018. This sample SOP addendum does not address every
More informationHEALTH RESEARCH ETHICS COMMITTEES Human Research (HREC)
HEALTH RESEARCH ETHICS COMMITTEES Human Research (HREC) STANDARD OPERATING PROCEDURES AND GUIDELINES May 2010 Contact Person: Dr Nicola Barsdorf nbarsdorf@sun.ac.za Tel +2721 938 9075 www.sun.ac.za/rds/
More informationGeneral Administration GA STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility
General Administration GA 102.01 STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility Approval: Nancy Paris, MS, FACHE President and CEO (17 July 2014) (Signature and
More informationResource Document for IRB members
Resource Document for IRB members The purpose of this document is to provide new members and returning members of the Institutional Review Board (IRB) with: (a) An overview of the roles and responsibilities
More informationCLOSE OUT VISIT REPORT (NO CRF TO MONITOR)
Date: Page: 1 of 8 CLOSE OUT VISIT REPORT (NO CRF TO MONITOR) Protocol: PI Name: PI Address: Date of Visit: Monitor(s): Other Sponsor Personnel Present: Site Personnel Present at Visit (include names and
More informationNN SS 401 NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR SITE SELECTION AND QUALIFICATION
NN SS 401 NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR SITE SELECTION AND QUALIFICATION SOP: NN SS 401 Version No.: 2.0 Effective Date: 21Oct2016 SITE SELECTION AND QUALIFICATION Supercedes Document:
More informationCHAPTER 2 STUDY POLICIES
CHAPTER 2 STUDY POLICIES CHAPTER 2 STUDY POLICIES 2.1 ADHERENCE TO MANUAL OF PROCEDURES The entire COBLT Study Group participates in the development, review, and acceptance of this Manual of Procedures.
More informationHIC Standard Operating Procedure. For-Cause Audits of Human Research Studies
HIC Standard Operating Procedure For-Cause Audits of Human Research Studies Background As part of the Wayne State University (WSU) Human Investigation Committee s (HIC) Human Research Protection Program,
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Adverse Event Identification, Recording and Reporting in Clinical Trials of Investigational Medicinal SOP-RES-019 Version Number 2 Issue Date 08 th Dec
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Urgent Safety Measures SOP-RES-022 Version Number 1 Issue Date 30 th April 2014 Effective Date 28 th May 2014 Review Date 28 th May 2016 Author(s) Reviewer(s)
More informationPrivacy Board Standard Operating Procedures
Privacy Board Standard Operating Procedures Page 1 of 12 I. Background The Health Insurance Portability and Accountability Act ( HIPAA ) generally requires specific compliance reviews and documentation
More information1. Department of Defense (DoD) Human Subjects Protection Regulatory Requirements
Information for Investigators: Headquarters, U.S. Special Operations Command Human Research Protection Office (HRPO) Human Research Protections Regulatory Requirements 1. Department of Defense (DoD) Human
More informationPOINT Trial Organization
3.0 STUDY ORGANIZATION The POINT study is a collaboration of established research networks connected through the leadership of the Principal investigators. Day to day operational oversight is provided
More informationEffective Date: April 2014 Revision: September 29, Executive Chair, Co-Chairs, NSHA REB Members, REB Office Personnel, Researchers.
TITLE: Standard Operating Procedure (SOP) External Inspections or Audits NUMBER: NSHA REB-SOP-9-002 Effective Date: April 2014 Revision: September 29, 2017 Applies To: Executive Chair, Co-Chairs, NSHA
More informationDepartment of Defense Human Research Protection Program DOD INSTITUTIONAL AGREEMENT FOR INSTITUTIONAL REVIEW BOARD (IRB) REVIEW (IAIR)
Department of Defense Human Research Protection Program DOD INSTITUTIONAL AGREEMENT FOR INSTITUTIONAL REVIEW BOARD (IRB) REVIEW (IAIR) General Instructions to Institutions and IRBs This form should be
More informationVersion 1.1, 6/30/2016 Guidance for Abbreviated IDE Requirements
Version 1.1, 6/30/2016 Guidance for Abbreviated IDE Requirements The Principal Investigator of a study that is requesting an abbreviated IDE for use of a non-significant risk device must attest to the
More informationQUALITY TIPS FOR CLINICAL SITES. Athena Thomas-Visel. Clinical Quality Consultant QUALITY TIPS FOR CLINICAL SITES
QUALITY TIPS FOR CLINICAL SITES Athena Thomas-Visel Clinical Quality Consultant QUALITY TIPS FOR CLINICAL SITES Purpose of presentation: Share best practices seen from 150+ sites visited Spark conversation
More informationToward Greater Scientific Rigor
Toward Greater Scientific Rigor Good Clinical Practice (GCP) A NEW REQUIREMENT! The Center for Clinical & Translational Science 205.934.7442 ccts@uab.edu www.uab.edu/ccts @cctsnetwork The requirement:
More informationHuman Research Protection Program Institutional Review Board
Human Research Protection Program Institutional Review Board Policies and Procedures Guidebook TABLE OF CONTENTS Federal, State and University Regulations Related to the IRB... Section 1.0 Definition of
More informationSTANDARD OPERATING PROCEDURE SOP 325
STANDARD OPERATING PROCEDURE SOP 325 STUDY START UP ACTIVITIES FOR CLINICAL RESEARCH TRIALS Version 1.4 Version date 28.03.2017 Effective date 28.03.2017 Number of pages 7 Review date April 2019 Author
More informationRESEARCH SUPPORTED BY A DEPARTMENT OF DEFENSE (DOD) COMPONENT
DUKE UNIVERSITY HEALTH SYSTEM Human Research Protection Program RESEARCH SUPPORTED BY A DEPARTMENT OF DEFENSE (DOD) COMPONENT 2/19/2016 The following special considerations apply to research involving
More informationCLIC Clinical Investigator (And Site Staff) Certification
CLIC Clinical Investigator (And Site Staff) Certification CLIC Level 1: 23-24 March 2015 CLIC Level 2: 25-27 March 2015 Cape Town (Venue to be confirmed) C PD points L e v e l 1 : 1 4 G e n e r a l, 2
More informationLOUIS STOKES CLEVELAND VA MEDICAL CENTER RESEARCH SERVICE Human Subject Protection Standard Operating Procedure (SOP)
LOUIS STOKES CLEVELAND VA MEDICAL CENTER RESEARCH SERVICE Human Subject Protection Standard Operating Procedure (SOP) Effective Date: February 7, 2013 SOP Title: Study Monitoring Visits - Process for Access
More informationTraining, Site Selection and Human Subject Protection: Factors to Consider When Developing a Monitoring Plan
Training, Site Selection and Human Subject Protection: Factors to Consider When Developing a Monitoring Plan Cynthia F. Kleppinger, M.D. Senior Medical Officer Office of Scientific Investigations Office
More informationSTUDY INFORMATION POST-IRB APPROVAL FDA DEVICE (IDE) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR 812)
POST-IRB APPROVAL FDA DEVICE (IDE) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR 812) Purpose: Investigators who initiate and submit an IDE application to the FDA assume the responsibilities of both
More informationVCU Clinical Research Quality Assurance Assessment
VCU Clinical Research Quality Assurance Assessment Principal Investigator Protocol Title Protocol IRB Number Name of Person Completing Assessment Date Assessment was Completed The goal of this assessment
More informationPrepared by the American College of Radiology Imaging Network Protocol Development and Regulatory Compliance Department
AUDIT MANUAL Prepared by the American College of Radiology Imaging Network Protocol Development and Regulatory Compliance Department Original: October 2001 Revised: June 2010 American College of Radiology
More informationGenesis Health System. Institutional Review Board. Standard Operating Procedures
Genesis Health System Institutional Review Board Table of Contents 1. INSTITUTIONAL AUTHORITY... 6 2. PURPOSE... 6 3. THE SCOPE & AUTHORITY OF THE IRB... 7 Scope...7 Authority of the GHS-IRB...7 Authority
More informationAuditing of Clinical Trials
Version 1.2 Effective date: 3 September 2012 Author: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision Chronology: Effective Date Version 1.2 3 Sept 2012 Version 1.1 12 May
More informationHuman Research Ethics Review Policy
Policy Document Title: Document ID: Document Name: Human Research Ethics Review Policy PY-RSH-300305 Human Research Ethics Review Policy Version Number: 2 Revision Date: Key Words 28/10/2014 10:54:00 AM
More informationImplementing the Revised Common Rule Exemptions with Limited IRB Review
Implementing the Revised Common Rule Exemptions with Limited IRB Review Introduction: Four of the exempt categories in the revised Common Rule include a provision for limited IRB review. This resource
More informationIRB 101. Rachel Langhofer Joan Rankin Shapiro Research Administration UA College of Medicine - Phoenix
IRB 101 Rachel Langhofer Joan Rankin Shapiro Research Administration UA College of Medicine - Phoenix Contents Brief discussion of regulations IRB Structure Levels of Approval Informed Consent HIPAA/HITECH
More informationClinical Trial Quality Assurance Common Findings
Clinical Trial Quality Assurance Common Findings Objectives Identify common findings found in research study reviews conducted by the CTQA Program Understand what findings require an action plan vs. a
More informationINDIANA STATE UNIVERSITY POLICIES AND PROCEDURES FOR THE REVIEW OF RESEARCH INVOLVING HUMAN SUBJECTS
INDIANA STATE UNIVERSITY POLICIES AND PROCEDURES FOR THE REVIEW OF RESEARCH INVOLVING HUMAN SUBJECTS This manual is believed to be in full compliance with all applicable Federal and state laws and regulations.
More informationSession 3 FDA Audits and Findings
Session 3 FDA Audits and Findings Byungja Marciante, Investigator US Food and Drug Administration Shanghai Centre-Suite 723 1376 Nanjing Xi Lu Shanghai, PRC 200040 美国食品药品管理局上海商城 723 室南京西路 1376 号中国上海 200040
More information